254. Porphyria
59 clinical trials,   52 drugs   (DrugBank: 17 drugs),   17 drug target genes,   33 drug target pathways

Searched query = "Porphyria", "CEP", "Erythropoietic protoporphyria", "EPP", "X-linked dominant protoporphyria", "XLDP", "PCT", "HEP", "AIP", "ADP", "VP", "Hereditary coproporphyria", "HCP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-002863-28-GB
(EUCTR)
26/09/200715/08/2007Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001 Erythropoietic protoporphyria (EPP)
MedDRA version: 9.1;Level: LLT;Classification code 10015289;Term: Erythropoietic protoporphyria
Trade Name: Questran
Product Name: Questran
INN or Proposed INN: COLESTYRAMINE
Guy's & St Thomas' NHS Foundation TrustNULLNot RecruitingFemale: yes
Male: yes
21Phase 4United Kingdom